🚨 INDV: Indivior and Supernus Forge a Merger of Equals, Creating a $2.2B CNS Biopharma Powerhouse

New Filing: 8-K

Ticker: INDV | Score: 10/10 | Sentiment: Positive

Summary (Wiseek AI)

Indivior and Supernus Pharmaceuticals have announced a merger of equals, blending complementary CNS portfolios into a company with ~$2.2B in annual revenue. A $1B special dividend will be paid to Indivior stockholders before closing, and Supernus CEO Jack Khattar will lead the combined entity.

Further Research: 🤖 Wiseek AI Analysis | 🏛️ Original SEC Filing

Automated via Wiseek.ai — Identifying market-moving SEC filings & news.